^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

    i
    Other names: RICTOR, RPTOR Independent Companion Of MTOR Complex 2, Rapamycin-Insensitive Companion Of MTOR, AVO3 Homolog, Pianissimo, HAVO3, RPTOR Independent Companion Of MTOR Complex 2, TORC2-Specific Protein AVO3, KIAA1999, AVO3, PIA
    1m
    Alternative Lengthening of Telomeres in Malignant PEComas: Correlation with Molecular Features Including ATRX Gene Mutation Status. (PubMed, Mod Pathol)
    Our study provides the first correlation between ALT and genomic features of malignant PEComas, demonstrating that ATRX alterations invariably predict ALT, but that a subset of tumors without mutations in known ALT suppressor genes also activate ALT. These findings confirm that the association between ATRX alterations and ALT observed in other tumor types applies to PEComas and indicate that in a subset of cases, ALT may be activated by ATRX independent mechanisms.
    Journal
    |
    ATRX (ATRX Chromatin Remodeler) • TSC1 (TSC complex subunit 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    1m
    A novel oncogenic nonsense mutation of SMARCA4 and genetic characteristic analysis of SMARCA4 (BRG1)-deficient undifferentiated tumor of the bladder. (PubMed, Virchows Arch)
    This suggests that besides SMARCA4 deficiency, alterations in other genes may cooperatively contribute to the tumorigenesis of bladder undifferentiated tumors. These findings provide a reference for subsequent exploration of precise diagnostic and prognostic assessment and treatment strategies for this disease.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • KMT2C (Lysine Methyltransferase 2C) • FGF3 (Fibroblast growth factor 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • FGF4 (Fibroblast growth factor 4) • GLI1 (GLI Family Zinc Finger 1) • STAG2 (Stromal Antigen 2) • FLT4 (Fms-related tyrosine kinase 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA3 (EPH receptor A3)
    2ms
    Genomic characterization and prognosis of pancreatic adenosquamous carcinoma. (PubMed, Pancreatology)
    Pathway enrichment analysis indicated that STK11 mutations, high tumor mutational burden (TMB-H), APC deletion, TERT/RICTOR amplification, and chromosomal instability (CIN-H) were significantly associated with altered pathways. Additionally, we confirmed the prognostic value of our PASC-specific signature through validation in an independent cohort of pancreatic ductal adenocarcinoma patients.
    Journal • Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    TP53 mutation • TMB-H • STK11 mutation • CDKN2A deletion
    2ms
    SLAP controls mTORC2 integrity via UBE3C-mediated non-degradative mLST8 ubiquitination to suppress colorectal tumorigenesis. (PubMed, Cell Death Differ)
    The mechanistic target of rapamycin complex 2 (mTORC2) signaling pathway, which regulates cell growth and migration, exhibits oncogenic function in colorectal cancer (CRC)...In immunodeficient mice CRC xenografts, SLAP depletion enhanced mTORC2 activity and sensitized CRC cells to mTOR catalytic inhibitors. Together, our findings reveal a previously unrecognized SLAP-UBE3C-mLST8 axis that regulates mTORC2 integrity and suggest a potential therapeutic avenue for targeting mTORC2 in CRC.
    Journal
    |
    RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    sirolimus
    2ms
    Primary Cutaneous CD30-Positive Lymphoproliferative Disorder With Gamma-Delta T-Cells: A Molecular-Annotated Case With a Classic Clinical Appearance and Behavior. (PubMed, J Cutan Pathol)
    Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LRP1B (LDL Receptor Related Protein 1B) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA7 (EPH Receptor A7)
    |
    HER-2 mutation • TNFRSF8 positive
    2ms
    Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis. (PubMed, Front Oncol)
    This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CSF3R (Colony Stimulating Factor 3 Receptor) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDIT4 (DNA Damage Inducible Transcript 4) • PGK1 (Phosphoglycerate Kinase 1)
    3ms
    Bioinformatics Approach to mTOR Signaling Pathway-Associated Genes and Cancer Etiopathogenesis. (PubMed, Genes (Basel))
    By distinguishing shared drivers from tumor-specific nodes and elevating non-mutated, topology-inferred candidates, the approach refines biomarker discovery and suggests architecture-aware therapeutic strategies. The analysis is reproducible and extensible, supporting prospective validation of prioritized candidates and the design of correlative studies that align pathway activity with clinical response.
    Journal
    |
    PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TSC2 (TSC complex subunit 2) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    3ms
    PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance. (PubMed, Ther Adv Med Oncol)
    A genomic expression analysis performed in Cohort #3 (n = 35) showed that a downregulation in the PI3K/AKT/mTOR pathway was mainly evident in the GP group of patients. This integrated multi-step analysis identified potentially altered pathways with a biological impact on squamous-NSCLC oncogenesis, suggesting that the PI3KCA/mTOR pathway could affect the prognosis of resected SCC patients through both genomic aberrations and impaired expression.
    Journal
    |
    SMAD4 (SMAD family member 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDR2 (Discoidin domain receptor 2)
    |
    PIK3CA mutation
    4ms
    Molecular co-alteration patterns of RICTOR-mutant metastatic lung adenocarcinomas: a single-center cohort study. (PubMed, Virchows Arch)
    RICTOR mutations in lung adenocarcinoma define a molecularly distinct subgroup characterized by preferential co-occurrence with EGFR, KRAS, and TP53, as well as a broader spectrum of genomic alterations. These findings support the view that RICTOR functions within complex oncogenic contexts and warrant further investigation in larger, multi-institutional cohorts.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • EML4 (EMAP Like 4) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • EGFR mutation • PIK3CA mutation • BRAF V600 • EGFR exon 20 insertion • ALK rearrangement • ALK fusion • KEAP1 mutation • ROS1 rearrangement • EGFR G719X
    5ms
    Precise and In Vivo-Compatible Spatial Proteomics via Bioluminescence-Triggered Photocatalytic Proximity Labeling. (PubMed, ACS Cent Sci)
    Additionally, BRET-ID identifies G3BP1-interacting proteins in arsenite-stressed cells and tumor xenografts, uncovering novel stress granule components, including the mTORC2 subunit RICTOR. BRET-ID serves as a powerful genetically encoded tool for studying protein localization and molecular interactions in living organisms.
    Preclinical • Journal
    |
    RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • G3BP1 (G3BP Stress Granule Assembly Factor 1)
    5ms
    Sellar Metastatic Follicular Thyroid Carcinoma With Novel Mutations Clinically Mimicking Pituitary Macroadenoma: Intraoperative Frozen Section Diagnosis Challenges. (PubMed, Anticancer Res)
    This case is a rare example of FTC with novel mutations clinically and radiologically mimicking pituitary macroadenoma and illustrates the importance of rigorous histological analysis for accurate diagnosis, particularly during the intraoperative consultation, to ensure proper treatment.
    Journal
    |
    mTOR (Mechanistic target of rapamycin kinase) • FANCA (FA Complementation Group A) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • NKX2-1 (NK2 Homeobox 1) • PAX8 (Paired box 8)
    5ms
    SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (clinicaltrials.gov)
    P=N/A, N=50000, Recruiting, Massive Bio, Inc. | Trial completion date: Jun 2027 --> Jun 2040 | Trial primary completion date: Dec 2026 --> Dec 2038
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FGFR2 (Fibroblast growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • STK11 (Serine/threonine kinase 11) • NPM1 (Nucleophosmin 1) • HRAS (Harvey rat sarcoma viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • RB1 (RB Transcriptional Corepressor 1) • CLDN18 (Claudin 18) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NF1 (Neurofibromin 1) • JAK2 (Janus kinase 2) • NRG1 (Neuregulin 1) • POLE (DNA Polymerase Epsilon) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PD-1 (Programmed cell death 1) • CCND1 (Cyclin D1) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • VEGFA (Vascular endothelial growth factor A) • BCL6 (B-cell CLL/lymphoma 6) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • PTCH1 (Patched 1) • FGFR4 (Fibroblast growth factor receptor 4) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • MAP2K2 (Mitogen-activated protein kinase kinase 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • WT1 (WT1 Transcription Factor) • ATRX (ATRX Chromatin Remodeler) • BRCA (Breast cancer early onset) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • TSC2 (TSC complex subunit 2) • CHEK2 (Checkpoint kinase 2) • PD-L2 (Programmed Cell Death 1 Ligand 2) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • JAK1 (Janus Kinase 1) • FANCA (FA Complementation Group A) • TSC1 (TSC complex subunit 1) • MDM4 (The mouse double minute 4) • POLD1 (DNA Polymerase Delta 1) • CDK6 (Cyclin-dependent kinase 6) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • AURKA (Aurora kinase A) • JAK3 (Janus Kinase 3) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • CHEK1 (Checkpoint kinase 1) • GATA6 (GATA Binding Protein 6) • MSH3 (MutS Homolog 3) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • GNAS (GNAS Complex Locus) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • AKT2 (V-akt murine thymoma viral oncogene homolog 2) • CCND2 (Cyclin D2) • CCND3 (Cyclin D3) • CSF1R (Colony stimulating factor 1 receptor) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • HDAC1 (Histone Deacetylase 1) • PRDM1 (PR/SET Domain 1) • ZNF217 (Zinc Finger Protein 217) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • GATA3 (GATA binding protein 3) • PARP2 (Poly(ADP-Ribose) Polymerase 2) • PARP3 (Poly(ADP-Ribose) Polymerase Family Member 3) • SDHA (Succinate Dehydrogenase Complex Flavoprotein Subunit A) • ACVR1B (Activin A Receptor Type 1B) • ZNF703 (Zinc Finger Protein 703)
    |
    HER-2 mutation • AKT1 mutation